AptaBio Therapeutics Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-20,297	-12,062	-10,565
Depreciation & Amortization	541.25	539.11	484.62
Loss (Gain) From Sale of Investments	759.56	244.29	2,494
Loss (Gain) on Equity Investments	324.3	4.19	-
Stock-Based Compensation	242.08	186.65	123.6
Other Operating Activities	4,279	-2,458	631.31
Change in Other Net Operating Assets	-743.15	-549.77	-1.91
Operating Cash Flow	-16,000	-14,095	-6,833
Capital Expenditures	-1,101	-1,345	-1,041
Sale (Purchase) of Intangibles	-46.6	-46.6	-10.36
Investment in Securities	16,057	-9,006	5,332
Other Investing Activities	42.24	60.15	27.66
Investing Cash Flow	14,579	-12,737	1,743
Long-Term Debt Issued	-	38,900	-
Long-Term Debt Repaid	-	-127.85	-87.95
Net Debt Issued (Repaid)	-132.19	38,772	-87.95
Issuance of Common Stock	-	-	589.2
Other Financing Activities	-23.16	-19.2	-5.24
Financing Cash Flow	-153.81	49,854	496.01
Foreign Exchange Rate Adjustments	-4.78	5.07	16.76
Miscellaneous Cash Flow Adjustments	-0	-0	0
Net Cash Flow	-1,579	23,027	-4,577
Free Cash Flow	-17,101	-15,440	-7,874
Free Cash Flow Margin	-588.43%	-4767.39%	-16284.04%
Free Cash Flow Per Share	-760.31	-692.42	-353.27
Cash Interest Paid	10.75	11.47	4.49
Cash Income Tax Paid	99.72	48.45	-34.01
Levered Free Cash Flow	-946.18	-13,398	-
Unlevered Free Cash Flow	1,349	-12,659	-
Change in Net Working Capital	-14,154	1,429	-

Source: S&P Capital IQ. Standard template. Financial Sources.